The bacterial superantigen staphylococcal enterotoxin (SE) A (SEA) directs cytotoxic T lymphocytes (CTLs) expressing particular sequences of the T-cell receptor (TCR) 
hydrophilic spacer. The C215-SEA conjugate targeted CD4' as well as CD8' CTLs to lyse a panel of colon carcinoma cells lacking M$C class H molecules. T-cell recognition of mAb-SEA conjugates was SEA specific, since SEB-selective T-cell lines with potent cytotoxic activity towards Raji cells coated with SEB did not respond to the C215-SEA conjugate. Unconjugated SEA did not induce T-cell lysis of MHC class I-colon carcinoma cells but efficiently directed CTLs against MHC class HI RaJi cells and certain interferon-treated MHC class II+ colon carcinoma cells. These results suggest that SEA-mAb conjugates retain the SEA-related selectivity for certain TCR 13-chain variable region (Va) sequences but, in contrast to unconjugated SEA, mediate the TCR interaction in a MHC dass Il-independent manner. The cytotoxic activity mediated by C215-SEA and C242-SEA conjugates was blocked by excess of C215 mAb and C242 mAb, respectively, showing that the specificity in the targeting ofmAb-SEA conjugates is defined by the antigen reactivity of the mAb. These results demonstrate that bacterial superantigens may be successfully conjugated to mAb with preserved T cell-activating capacity. The circumvention of MHC class II binding of SEs by conjugation to mAb suggests that such conjugates may find general application as antitumor agents, taking advantage of the extreme T cellactivating potency of superantigens.
The collection of superantigens consists of bacterial exoproteins, such as the structurally related staphylococcal and streptococcal exotoxins, but also endogenous self superantigens, including the mammary tumor virus-encoded Mls antigens (1) (2) (3) . They are characterized by the capacity to stimulate in a major histocompatibility complex (MHC) class II-dependent manner a high frequency of T cells bearing particular T-cell receptor (TCR) 13-chain variable segments (Vat) (1, (4) (5) (6) (7) (8) (9) (10) . Studies on the staphylococcal enterotoxins (SEs) A and B (SEA and SEB) and toxic shock syndrome toxin 1 have shown high-affinity binding to MHC class II molecules (4) (5) (6) (10) (11) (12) . SEA, SEB, and toxic shock syndrome toxin 1 bind to a variety of different MHC class II isotypes and allotypes, and the binding seems to involve conserved peptide sequences expressed on both the MHC class II a and 13 chains (9) (10) (11) (12) (13) . T cells recognizing the MHC class II-SE complex are activated to proliferation, cytokine production, and cytotoxicity (14) (15) (16) (17) (18) (19) . The SE-dependent cell-mediated cytotoxicity (SDCC) results in elimination of MHC class Il-expressing SE-presenting target cells (17) (18) (19) .
Studies on fresh MHC class II' leukemic cells have suggested that the SDCC mechanisms may be a useful tool for therapeutic elimination of MHC class I1I tumor cells (16). However, since MHC class Il-expressing tumor types only represent a minority of the most frequent human tumors and systemic T-cell activation is expected to result in severe toxicity, it seems reasonable to assume that the SDCC mechanism will not have general application in the treatment of human malignant diseases. During the last decade monoclonal antibodies (mAbs) have been evaluated for tumor therapy, either as native antibodies or conjugated to radioactive isotopes, cytotoxic drugs, or plant toxins (20) (21) (22) (23) . Recent attempts have also included polyclonal activation of T lymphocytes by antibody heteroconjugates simultaneously recognizing tumor cells and the CD3/TCR complex on T cells (24) (25) (26) . The direct binding of antibody heteroconjugates to the T cell may be a major drawback in vivo, counteracting mAb localization at the tumor site. In this report we demonstrate that conjugates between SEA and mAbs recognizing human colon cancer enable T cells to lyse colon carcinoma cells in vitro. The mAb-SEA conjugates direct cytotoxic T lymphocytes (CTLs) against target cells expressing the mAbdefined cell-surface antigen independent of their MHC expression. In contrast to antibody heteroconjugates, the mAb-SEA conjugates do not engage T cells prior to binding to the target cell. We believe that mAb-superantigen-based conjugates represent a novel and powerful approach to tumor therapy, which may have significant advantages in comparison with earlier described antibody-based therapies. (29) . The spacers ended with reactive iodine groups which reacted with the mercapto groups introduced on SEA, resulting in the formation of stable thioether linkages. The synthesized mAb-SEA conjugate was fractionated'on a Superdex 200 HR 16/50 column (Pharmacia) and was eluted with 2 mM phosphate buffer, pH 7.5/0.15 M NaCl. Fractions with the desired product were pooled and analyzed by SDS/PAGE on Phast-Gel5 gradient 4-15 and silver staining (Pharnacia). The conjugates contained zero to three SEA molecules per mAb molecule (average one for C215-SEA and two for C242-SEA). (Fig. 1A) . We demonstrated earlier (4) that SEA bound with high affinity to MHC class II molecules on Raji cells. Fluorescence-activated cell sorter analysis showed that SEA and C215-SEA, but not unconjugated C215, bound strongly to Raji cells (Fig. LA) . The binding ofC215-SEA to Raji cells was efficiently blocked by SEA but not by C215 (data not shown). Thus, in addition to mAb specificity, the C215-SEA conjugate has retained the capacity of SEA to bind to cells expressing MHC class II molecules. To compare the relative MHC class II binding affinity of SEA and C215-SEA, respectively, we utilized a cell-binding assay with 125I-SEA and C215-125I-SEA. Inhibition studies showed that "2I-SEA was displaced in a dose-dependent manner by SEA and C215-SEA mAb (Fig. 1B) . Similarly, C215-125I-SEA binding to Raji cells was efficiently blocked by SEA and C215-SEA, which indicates that the C215-SEA binding is specific for the MHC class II molecule (Fig. 1B) . Assuming that the C215-SEA conjugate contains about 15% SEA, the conjugate apparently displays identical MHC class II binding as SEA on a molar basis.
MATERIALS AND METHODS
T-CelI Targeting by the C215-SEA Conjugate. The C215-SEA conjugate efficiently directed SEA-responsive CTLs to mediate cytotoxicity against the SW620 colon carcinoma cells, whereas a mixture of unconjugated SEA and C215 mAb had no effect (Fig. 2) . Cytotoxicity against SW620 cells was induced by C215-SEA at effector-to-target ratios as low as 3:1, while unconjugated SEA and C215 mAb lacked effect even at 30:1. Lysis was recorded at 3 ,ug of the conjugate per ml, whereas SEA at 1000-fold higher concentrations only had marginal effects (Fig. 2) . The SW620 cell line did not constitutively or after interferon treatment express surface MHC class II molecules, as analyzed by immunoprecipitation and flow cytometry with a panel of mAbs against the HLA-DR, HLA-DP, and HLA-DQ isotypes (27) . Furthermore, Northern blot analysis demonstrated absence of HLA-DRa, HLA-DR8, invariant chain, and HLA-DZa transcripts in SW620 cells (27) . C215-SEA conjugate-induced cytotoxicity was observed against several MHC class II-C215+ colon carcinoma cell lines, including WiDr, COLO 205, and SW620 (Fig.  2) . Unconjugated SEA (Fig. 2) Target  Control  SEA  C215-SEA  CD4+  SW620  2  5  50  CD4+  Raji  0  41  43  CD8+  SW620  0  1  23  CD8+ Raji 2 72 68 *The CTLs (SEA-3) were used at effector-to-target ratio of30:1 in the absence (control) or presence of SEA and C215-SEA at 1 jig/ml. sensitivity to lysis at low concentrations of the C215-SEA conjugate but resistance to unconjugated SEA and C215 mAb (Fig. 2) . Interferon y treatment of COLO 205 cells resulted in strong expression of HLA-DR and HLA-DP molecules (27) and sensitivity to CTL lysis at similar concentrations of SEA and C215-SEA (Fig. 2) (Fig. 3) . In contrast, the SEBresponsive CTLs demonstrated strong cytotoxicity against SEB-coated Raji cells (Fig. 3) .
Specificity of the mAb-SEA Conjugate Is Defined by the mAb. To demonstrate that the target selectivity of the mAb-SEA conjugate is entirely dependent on the mAb specificity, we performed criss-cross inhibition experiments with unconjugated C215 and C242 mAbs and C215-SEA and C242-SEA conjugates. Cytotoxicity mediated by C215-SEA and C242-SEA was blocked by addition of excess unconjugated C215 and C242, respectively but was not influenced by addition of the irrelevant mAb binding to the same target cell (Fig. 4) or high concentrations of isotype-specific control antibodies (data not shown).
DISCUSSION
CTLs with specificity for antigens expressed on tumor cells have been demonstrated in patients with malignant melanoma and renal cancer (30, 31) . However, they are in most cases infrequent and obviously not capable of protecting the host against the growing tumor. The superantigen SEA allows activation of a frequency of T cells (>10%6) even higher than that observed during the response to allogenic MHC in organ transplantation. Since the latter inevitably results in rejection of the transplant, utilization of SEA to direct a high frequency of T cells towards a tumor may hopefully ensure a similar outcome. In this paper we describe such an approach to tumor therapy. Conjugation of SEA to mAb directed against human colon carcinomas provided an agent that was able to selectively target SEA-responsive CTLs against the tumor cells. Earlier studies in our and other laboratories have demonstrated that binding of SEA to MHC class II molecules is a prerequisite for subsequent activation and targeting of T cells (4) (5) (6) 15) . The SEA-mAb-mediated cytotoxicity apparently is MHC class II independent and does not require antigen-specific effector CTLs. The specificity at the target level is defined by the mAb and at the CTL level by the expression of relevant TCR Vp sequences, suitable for interaction with SEA.
The SW620 colon carcinoma cell line, which lacked mRNA transcripts for HLA-DRa, HLA-DR(3, HLA-DZa, and invariant chain and failed to express surface MHC class II antigens as analyzed by either immunoprecipitation or flow cytometry (27) efficiently presented C215-SEA but not SEA to CTLs. Conjugate-dependent killing not only was restricted to SW620 cells but also was recorded for MHC class 1I-COLO 205 and WiDr cell lines as well as freshly isolated MHC class II-human colon carcinoma cells (data not shown). The existence of MHC class II-independent T-cell activation induced by bacterial superantigens is supported by recent studies by Fleischer and co-workers (32 (33, 34) . The determination of the amino acids necessary for MHC class II binding may provide a rationale to obtain mAb-SEA conjugates with preserved T cell-activating properties but totally devoid of binding to MHC class II molecules.
Antibody heteroconjugates and hybrid mAbs reacting with tumor cells and epitopes involved in T-cell activation, including the CD3-TCR complex, CD2, or CD28, have been used to target T cells to kill tumor cells in vitro (24-26, 35, 36) . However, bispecific mAbs have several limitations as therapeutic agents: (i) the ability to directly bind to the T cells will ultimately lead to capture of the intravenously administered mAb in peripheral blood and perturb tissue penetration, (it) binding to T cells in the absence of proper cross-linking by the target cell may lead to anergy (37) or cell death (38) , and (iii) activation of an excessive number of T cells by pan-T-cell heteroconjugates may result in a cytokine-related shock syndrome and suppression of specific immunity dealing with infectious pathogens (39) . In contrast, mAb-SEA conjugates do not suffer from these limitations. The ability of the conjugate to efficiently interact with T cells only when bound to the tumor cell surface allows effective tissue penetration and avoids unwanted systemic T-cell activation. Moreover, local production of lymphokines by T cells activated in the tumor area may be expected to result in a beneficial inflammatory response with direct effects on the tumor cells as well as recruitment of new anti-tumor effector cells in a cascade fashion. SEA is an extremely efficient inducer of interleukin 2, tumor necrosis factor, and y interferon (14, 40) . The activation of a limited fraction of T cells bearing the proper TCR Vp sequences preserves a large portion of the T-cell repertoire for dealing with specific immunity. Recently attempts to target antigen-specific CD4+ T cells against tumor cells have been made with conjugates of mAbs and recall antigens such as keyhole limpet hemocyanin (41) and purified protein derivative (42) . These mAb-antigen conjugates allowed presentation of relevant processed antigenic peptide fragments on MHC class II molecules and retargeting of CTLs to the tumor cells (41, 42 The mAb-SEA conjugates described in this study represent a novel class of anti-tumor agents based on conjugation of a superantigen to a tumor-reactive mAb. Development of superantigen-mAb-based agents may serve as an important immunotherapeutic strategy for treatment of malignant diseases that have escaped the host immune response.
